KETOROLAC TROMETHAMINE - ketorolac tromethamine solution/ drops Sun Pharmaceutical Industries, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use KETOROLAC TROMETHAMINE ophthalmic solution safely and effectively. See full prescribing information for KETOROLAC TROMETHAMINE ophthalmic solution. KETOROLAC TROMETHAMINE ophthalmic solution 0.5% Initial U.S. Approval: 1991 ------ INDICATIONS AND USAGE------

Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for:

- The treatment of inflammation following cataract surgery. (1)
- The temporary relief of ocular itching due to seasonal allergic conjunctivitis. (1)

One drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye(s) four times a day for relief of ocular itching due to seasonal allergic conjunctivitis.

For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period. (2.1)

Ophthalmic solution containing 5 mg/mL ketorolac tromethamine. (3)

- 5 mL size bottle filled with 3 mL of solution
- 5 mL size bottle filled with 5 mL of solution
- 10 mL size bottle filled with 10 mL of solution

CONTRAINDICATIONS
Hypersensitivity to any component of this product. (4)
WARNINGS AND PRECAUTIONS

- Delayed healing (5.1)
- Cross-sensitivity or hypersensitivity (5.2)
- Increased bleeding time due to interference with thrombocyte aggregation (5.3)
- Corneal effects including keratitis (5.4)

------ ADVERSE REACTIONS ------

The most frequent adverse reactions reported by up to 40% of patients participating in clinical trials have been transient stinging and burning on instillation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2018

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

2.2 Use with Other Topical Ophthalmic Medications

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Delayed Healing
- 5.2 Cross-Sensitivity or Hypersensitivity
- 5.3 Increased Bleeding Time
- 5.4 Corneal Effects
- 5.5 Contact Lens Wear

6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience
- 6.2 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- **11 DESCRIPTION**

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

- 17.1 Slow or Delayed Healing
- 17.2 Avoiding Contamination of the Product
- 17.3 Contact Lens Wear
- 17.4 Intercurrent Ocular Conditions
- 17.5 Concomitant Topical Ocular Therapy

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

Patient Dosing

The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day to the affected eye(s) for relief of ocular itching due to seasonal allergic conjunctivitis.

For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one

drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.

2.2 Use with Other Topical Ophthalmic Medications

Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

3 DOSAGE FORMS AND STRENGTHS

Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows:

- 5 mL size bottle filled with 3 mL of solution
- 5 mL size bottle filled with 5 mL of solution
- 10 mL size bottle filled with 10 mL of solution

4 CONTRAINDICATIONS

Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.

5 WARNINGS AND PRECAUTIONS

5.1 Delayed Healing

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

5.2 Cross-Sensitivity or Hypersensitivity

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

5.3 Increased Bleeding Time

With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti- inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.

5.4 Corneal Effects

Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.

Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

5.5 Contact Lens Wear

Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

Because cli nical studies are conducted under wi dely var ying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to t he rates in the clinical studies of another drug and may not reflect t he rates observed in practice.

The most fr equent adverse react ions reported with the use of k etorolac tro meth a mine ophthal mic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinic altrials.

Other adverse reactions occurring approxi mately 1 to 10% of the time during treatment with ketor olac trometh a mine ophthal mic solutions included aller gic reactions, corneal ede ma, iritis, ocular inflammation, ocular ir ritation, super ficial ker atitis, and super ficial ocular in fections.

Other adverse reactions reported rarely with the use of ketorolac tro metha mine ophthal mic solutions included: c orneal infiltrates, corneal ulcer, eye dry ness, headac hes, and visual disturbance (blurry vision).

6.2 Postmarketing Experience

The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5% or a combination of these factors, include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown [see Warnings and Precautions (5.2, 5.4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects. P regnancy Category C

Pregnancy Category C: Ketorolac tr o metha min e, ad ministered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/ kg/day, respectively. These doses are approxi mately 100 ti mes and 250 ti mes higher respectively than the max i m um recom mended hu man topical op hthal mic daily dose of 2 mg (5 mg / mL x 0.05 mL/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis. Additionally, when ad ministered to rats after Day 17 of gestation at oral doses up to 1.5 mg/ k g/day (approxi mately 40 ti mes the typical hu man topical ophthal mic daily dose), ketorolac tro me tha mine resulted in dystocia and increased pup mortality. There are no adequate a nd well-controlled studies in pregnant w o men. Keto ro lac t ro met ham ine op htha lm ic so lut i on should be used during pregnancy only if the potential bene fit j usti fies the p otential risk to the fetus.

Nonterato genic Effect s: Because of the known effects of prostaglandin-inhibiting drugs on the fetal c ardio vascul ar syst em (closure of the ductus art eriosu s), the use of keto ro lac t ro met ham ine op htha lm ic so lut i on during late pregnancy should be avoided.

8.3 Nursing Mothers

Because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.

8.4 Pediatric Use


Safety and efficacy in pediatric patients below the age of 2 have not been established.

8.5 Geriatric Use

No overall clinical di fferences in sa fety or effectiveness have been observed between elderly and other ad ult patie nts.

11 DESCRIPTION

Keto ro lac t ro met ham ine op htha lm ic so lut i on 0.5% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthal mic use. Its che mical na me is (±)-5-Benzoyl-2, 3-dihydro-1H pyrrolizi ne-1-carboxylic acid co m pound with 2-a mino-2-(hydroxy methyl)-1,3-propanediol (1:1) and it has the following structure:



Keto ro lac t ro met ham ine op htha lm ic so lut i on is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. Keto ro lac t ro met ham ine op htha lm ic so lut i on is a race mic m ixture of R-(+) and S-(-)- ketor olac tro metha mine. Ketorol ac tro methamine may exist in t hree cr ystal for ms. All for ms are equally soluble in water. The pKa of ketorolac is 3.5. This white to o ff-white c rystalline su bstance discolors on prolonged exposure to light. The molecular weight of ketorolac tro metha mine is 376.41. The os molality of keto rolac t romet ham ine op htha lm ic so lut i on is 290 m O

s mol/kg.

Each mL of ketorolac tromethamine ophthalmic solution contains: **Active:** ketorolac tromethamine USP 0.5%. **Preservative:** benzalkonium chloride solution (50%) NF 0.02%. **Inactives:** edetate disodium USP 0.1%; octoxynol 40; water for injection USP; sodium chloride USP; hydrochloric acid NF and/or sodium hydroxide NF to adjust the pH.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Ketorolac tr o metha mine is a nonsteroidal ant i-inflammatory drug which, when a d ministered syste micall y, has de monstrated anal gesic, a nti-inflam matory, and anti-pyretic activity. The mechani sm of its action is thought to be due to i ts ability to inhibit prostaglandin biosynthesis.

12.3 Pharmacokinetics

Two drops of 0.5% ketorolac tro metha mine ophthal mic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved a mean ketorolac concentration of 95 ng/ mL in the aqueous h u mor of 8 of 9 eyes tested (range 40 to 170 ng/mL).

One drop of 0.5% ketorolac tro metha mine ophthal mic solution was instilled into 1 eye and 1 drop of vehicle into the other eye TID in 26 healthy subjects. Five (5) of 26 subjects had dete ctable concent ratio ns of ketorol ac in their plas ma (range 11 to 23 ng/mL) at Day 10 during topical ocular treat ment. The range of concent rations following TID dosing of 0.5% ketorolac tro metha mine ophthal mic solution are approximately 4 to 8% of the steady state mean minimum plas ma concentration observed following four times daily oral a d ministration of 10 mg ketorolac in humans (290 \pm 70 ng/mL).

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Ketorolac tr o metha mine was not carcinogenic in either rats given up to 5 mg/kg/day orally for 24 months or in mice given 2 mg /kg/day orally for 18 months. These doses are approximately 125 times and 50 times higher respectively than the maximum recommended human topical ophthal mic daily dose given as QID for itching to affected eyes on a mg/kg basis.

Ketorolac tromethamine was not mutagenic *in vitro* in the Ames assay or in forward mutation assays. Si milarly, it did not result in an *in vitro* increase in unscheduled DNA synthesis or an *in vivo* i ncrea se in chro moso me breakage in mice. However, ketorolac trometha mine did result in an increased incide nce in chro mosomal ab err atio ns in Chinese ha mster ovary cells.

Ketorol act ro metha mine did not i mpair fertility when ad ministered orally to male and fe male rats at doses up to 9 mg/kg/day and 16 mg/kg/day, respectively. These doses are respectively 225 and 400 ti mes higher than the typical h u man topical ophthal mic daily dose.

14 CLINICAL STUDIES

Two controlled clinical studies sho wed that k etorolac tro metha mine ophthal mic solution was significantly more effective than its vehicle in relieving ocular itching caused by seasonal all ergic conjunctivitis.

Two controlled clinical studies sho wed that pati ents t reated for two weeks with ket o rolac tro metha mi ne ophthal mic solution were less likely to have measurable signs of inflammation (cell and flare) than patients treated with its ve hicle.

Results from clinical studies indicate that k etorolac tro metha mine has no significant effect upon intraocular pressure; ho wever, chan ges in intraoc ular pressure may occur following cataract surgery.

16 HOW SUPPLIED/STORAGE AND HANDLING

Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows:

3 mL in 5 mL bottle	NDC 47335-219-90
5 mL in 5 mL bottle	NDC 47335-220-90
10 mL in 10 mL bottle	NDC 47335-221-90

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light.

17 PATIENT COUNSELING INFORMATION

17.1 Slow or Delayed Healing

Patie nts should be in for med of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).

17.2 Avoiding Contamination of the Product

Patie nts should be in structed to avoid allow ing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become cont a minated by common bacteria known to cause ocular infections. Serious da mage to the eye and subsequent loss of vision may result from using contaminated solutions.

Also, to avoid the potential for cross-conta mina tion, the patient should be advised to use one bottle for e ach eye foll owing bil ate ral ocular s u rgery. The use of the s a me bottle of topic al eye drops for both eyes following bilateral ocular surgery is not recommend ed.

17.3 Contact Lens Wear

Patients should be advised that keto ro lac t ro met ham ine op htha lm ic so lut i on should not be ad ministered while wearing contact lenses.

17.4 Intercurrent Ocular Conditions

Patients should be advised that if they develop an intercurrent ocular condition (e.g., trau ma or infection) or have ocular surgery, they should i mmediately seek their physician's advice concerning the continued use of keto ro lac t ro met ham ine op htha lm ic so lut i on.


17.5 Concomitant Topical Ocular Therapy

Patie nts should be advi sed that if more than one topical op ht hal mic medication is being used, the medicines should be ad ministered at least 5 minutes apart.

Distributed by: **Sun Pharmaceutical Industries, Inc.** Cranbury, NJ 08512 PJPI0496A ISS. 07/2017


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -label-3 mL

NDC 47335-219-90 Ketorolac Tromethamine Ophthalmic Solution 0.5% Rx only 3 mL




PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton- 3 mL

NDC 47335-219-90 Ketorolac Tromethamine Ophthalmic Solution 0.5% FOR USE IN THE EYES ONLY Rx only 3 mL SUN PHARMA



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Label -5 mL


NDC 47335-220-90 Ketorolac Tromethamine Ophthalmic Solution 0.5% Rx only 5mL



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton -5 mL


NDC 47335-220-90 Ketorolac Tromethamine Ophthalmic Solution 0.5% FOR USE IN THE EYES ONLY

Rx only 5 mL SUN PHARMA




PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - Label -10 mL

NDC 47335-221-90 Ketorolac Tromethamine Ophthalmic Solution 0.5% Rx only 10 mL



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -Carton -10 mL

NDC 47335-221-90 **Ketorolac Tromethamine Ophthalmic Solution** 0.5% FOR USE IN THE EYES ONLY Rx only 10 mL **SUN PHARMA**



KETOROLAC TROMET ketorolac tromethamine solution/					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code	(Source)	NDC:47	335-219
Route of Administration	OPHTHALMIC				
Active Ingredient/Active Moiety					
Ingr	redient Name]	Basis of Streng	th	Stren

Strength

UNII: YZI5105V0L)			18			
Inactive Ingred	ients					
		Ingredient Name			Sti	rength
BENZALKO NIUM C	HLORIDE (UNII: I	F5UM2KM3W7)				
EDETATE DISODIU	M (UNII: 7FLD91C	86K)				
OCTOXYNOL-40 (UNII: 9T1C662FKS)				
SODIUM CHLORID						
HYDRO CHLORIC A						
SODIUM HYDROXII WATER (UNII: 059Q		(321)				
WATER (ONE 055Q						
Packaging						
# Item Code		Package Description	Ma	rketing Start Date		eting End Date
1 NDC:47335-219- 90	1 in 1 CARTON		03/13/	/2018		
1	3 mL in 1 BOTTL Product	E, DROPPER; Type 0: Not a Combination				
N.F. 1	6					
Marketing In						
Marketing Catego	ory Applicatio	on Number or Monograph Citation		_	Marketin	ng End Date
			Marketi 0 3/13/20 18	_	Marketin	ng End Date
Marketing Catego	ory Applicatio			_	Marketin	ng End Date
Marketing Catego	Application	7		_	Marketin	ng End Date
Marketing Catego ANDA KETOROLA	C TROMET	'HAMINE		_	Marketin	ıg End Date
Marketing Catego	C TROMET	'HAMINE		_	Marketin	ng End Date
Marketing Catego ANDA KETOROLA	Application ANDA09001 C TROMET amine solution/o	'HAMINE		_	Marketin	ng End Date
Marketing Catego ANDA KETOROLA(ketorolac trometha	Application ANDA09001 C TROMET amine solution/o	7 'HAMINE drops	03/13/2018	_		ng End Date
Marketing Catego ANDA KETOROLA(ketorolac trometha Product Inform	Application ANDA09001 C TROMET Amine solution/ of Ation	7 'HAMINE drops	03/13/2018	3		
Marketing Catego ANDA KETOROLA(ketorolac trometha Product Inform Product Type	Application ANDA09001 C TROMET Amine solution/ of Ation	7 'HAMINE drops HUMAN PRESCRIPTION DRUG	03/13/2018	3		
Marketing Catego ANDA KETOROLAC ketorolac trometha Product Inform Product Type Route of Administ	Application ANDA09001 C TROMET amine solution/ of ation	7 'HAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC	03/13/2018	3		
Marketing Catego ANDA KETOROLAC ketorolac trometha Product Inform Product Type Route of Administ	Application ANDA09001 C TROMET amine solution/ of ation ration nt/Active Moi	7 'HAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC	03/13/2018	3 le (Source)	NDC:47	7335-220
Marketing Catego ANDA KETOROLAC ketorolac trometha Product Inform Product Type Route of Administa Active Ingredie	Application ANDA09001 C TROMET amine solution/or ation ration nt/Active Moint Ingr	THAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC ety edient Name	0 3/13/20 18	a le (Source) Basis of Strer	NDC:47	7335-220 Strength
Marketing Catego ANDA KETOROLAC ketorolac trometha Product Inform Product Type Route of Administa Active Ingredie	Application ANDA09001 C TROMET amine solution/or ation ration nt/Active Moint Ingr	7 'HAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC	0 3/13/20 18 Item Cod	3 le (Source)	NDC:47	7335-220
Marketing Catego ANDA KET OROLA(ketorolac trometha Product Inform Product Type Route of Administ Active Ingredie KETOROLAC TRO UNII:YZI5105V0L)	Application ANDA09001 C TROMET amine solution/or ation ation	THAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC ety edient Name	0 3/13/20 18 Item Cod	a de (Source) Basis of Strer ETOROLAC	NDC:47	7335-220 Strengtl 5 mg
Marketing Catego ANDA KET OROLA(ketorolac trometha Product Inform Product Type Route of Administr Active Ingredie KETOROLAC TRO UNII:YZI5105V0L)	Application ANDA09001 C TROMET amine solution/or ation ation	THAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC ety edient Name	0 3/13/20 18 Item Cod	a de (Source) Basis of Strer ETOROLAC	NDC:47	7335-220 Strength 5 mg
Marketing Catego ANDA KET OROLA(ketorolac trometha Product Inform Product Type Route of Administ Active Ingredie KETOROLAC TRO UNII:YZI5105V0L)	Application ANDA09001 C TROMET amine solution/ of ation ation nt/Active Moi Ingr METHAMINE (UN ients	7 'HAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC ety edient Name II: 4EVE5946BQ) (KETOROLAC - Ingredient Name	0 3/13/20 18 Item Cod	a de (Source) Basis of Strer ETOROLAC	NDC:47	7335-220 Strengtl 5 mg in 1 mL
Marketing Catego ANDA KETOROLAC ketorolac trometha Product Inform Product Type Route of Administa Active Ingredie KETOROLAC TRO	Application ANDA09001 C TROMET amine solution/ of ation ation ration nt/Active Moi Ingr METHAMINE (UN ients SHLORIDE (UNII: 1)	7 'HAMINE drops HUMAN PRESCRIPTION DRUG OPHTHALMIC ety edient Name II: 4EVE5946BQ) (KETOROLAC - III: 4EVE5946BQ) (KETOROLAC -	0 3/13/20 18 Item Cod	a de (Source) Basis of Strer ETOROLAC	NDC:47	7335-220 Strength 5 mg in 1 mL

S	SODIUM CHLORIDE (UNII: 451W47IQ8X)				
H	HYDRO CHLO RIC ACID (UNII: QTT17582CB)				
S	D DIUM HYDRO XI	DE (UNII: 55X04QC32I)			
W	ATER (UNII: 059Q	F0 KO0 R)			
Р	ackaging				
#	# Item Code Package Description Marketing Start Date			Marketing End Date	
1	NDC:47335-220- 90	1 in 1 CARTON	03/13/2018		
1 5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product					
N	Marketing Information				
N	Aarketing Catego	ry Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
A	NDA	ANDA090017	0 3/13/20 18		

K	ETOROLA	C TROMET	HAMINE				
ke	torolac trometha	amine solution/ o	lrops				
P	roduct Inform	ation					
Р	roduct T ype		HUMAN PRESCRIPTION DRUG	Ite m (Code (Source)	NDC:47	7335-221
R	oute of Administ	ration	OPHTHALMIC				
A	ctive Ingredie	nt/Active Moi	ety				
		Ingr	edient Name		Basis of Stren	gth	Strength
	ETOROLAC TRO NII:YZI5105V0L)	METHAMINE (UN	II: 4EVE5946BQ) (KETOROLAC -		KETOROLAC TROMETHAMINE		5 mg in 1 mL
Iı	nactive Ingred	ients					
			Ingredient Name			Sti	rength
B	ENZALKO NIUM C	CHLORIDE (UNII: H	5UM2KM3W7)				
EI	DETATE DISODIU	M (UNII: 7FLD91C8	36K)				
0	CTOXYNOL-40 (UNII: 9T1C662FKS)				
		E (UNII: 451W47IQ					
_	HYDRO CHLORIC ACID (UNII: QTT17582CB)						
-		DE (UNII: 55X04Q0	2321)				
W	ATER (UNII: 059Q	F0KO0R)					
P	ackaging						
#	Item Code		Package Description		Marketing Start Date		eting End Date

1 NDC:47335-221- 90	1 in 1 CARTON	0 3/13/20 18	
	10 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
Marketing In	formation		
Marketing Catego	ry Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090017	0 3/13/20 18	

Labeler - Sun Pharmaceutical Industries, Inc. (146974886)

Establishment

Name	Address	ID/FEI	Business Operations
Sun Pharmaceutical Industries Limited		725959238	ANALYSIS(47335-219, 47335-220, 47335-221), MANUFACTURE(47335-219, 47335-220, 47335-221)

Revised: 10/2018

Sun Pharmaceutical Industries, Inc.